Structure de mise en forme 2 colonnes

Context


Investigation on new therapeutic agents for chronic inflammatory diseases
Investigation on new therapeutic agents for chronic inflammatory diseases

It is estimated that inflammatory diseases affect more than 80 million people worldwide leading to untold suffering, economic loss and premature death. Considering life expectancy in Europe, these numbers are expected to increase in the next 20 years. Moreover, studies have shown that disorders such as rheumatoid arthritis (RA) can shorten life span by 10 years.

The treatment of chronic inflammatory disorders, including RA, remains a challenge for the medical and scientific community. The emergence of new drugs creates new options though it also entails high costs, complicated drug administration, allergic reactions and potentially fatal side effects.

 

Therefore more efficient strategies have to be identified in order to improve inflammatory disease treatment while decreasing the side effects with an improved cost-benefit ratio.

Nano-enabled drug delivery systems will take therapy of chronic inflammatory disorders to a new level by creating a new, highly specific and efficient strategy, with reduced treatment costs.

News and events

Breaking News:

14 May 2012

Next 30M NANOFOL Steering Committee/Workshop meeting

The next 30M NANOFOL Steering Committee/Workshop meeting will take place on May 31st and June 1st,...


>> see all news

The brochure

Nanofol.pdf

489 K

RSS feeds

Read it